Substance / Medication

Moroctocog alfa

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Real-world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe.
Blatný Jan, Nielsen Emma Munk, Reitzel Signe Baattrup et al. · Haemophilia · 2023
PMID: 37243934Meta-Analysis
Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa.
Pitance Victoire, Désage Stéphanie, Lienhart Anne et al. · Haemophilia · 2021
PMID: 33780111Observational
Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates.
Pouplard Claire, Sattler Laurent, Ryman Anne et al. · Haemophilia · 2020
PMID: 32107819Observational
Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.
Korth-Bradley Joan, Rupon Jeremy, Plotka Anna et al. · Clin Transl Sci · 2018
PMID: 29575770ObservationalFull text (PMC)
First observation of inhibitor development against efmoroctocog alfa in France.
Chamouni Pierre, Barbay Virginie, Billoir Paul et al. · Transfus Apher Sci · 2021
PMID: 33867284Case Report
Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa.
Megías-Vericat J E, Bonanad Boix S, Cid Haro A R et al. · Thromb Res · 2024
PMID: 38043392Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Moroctocog alfa (substance)
SNOMED CT
441764007
UMLS CUI
C0966500

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.